HCA Holdings halts the use of laparoscopic power morcellators in uterine fibroid surgeries in all 278 of its facilities, after the FDA raises the warning level on the cancer risk associated with the devices.
(Reuters) — HCA Holdings (NYSE:HCA), the largest for-profit U.S. hospital operator, said a procedure for removing uterine fibroids that's been linked to the spread of cancer will no longer be performed at its facilities.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1veHAeb
Cap comentari:
Publica un comentari a l'entrada